Previous work demonstrated that exogenous expression of Rybp (Ring 1 YY1-binding protein or DEDAF) kills tumor but not nontransformed cells. This tumor-preferential killing activity could be exploited in a gene therapy approach to treat cancer. To test the potential of viral-mediated delivery of Rybp as an anticancer treatment, we generated an adenovirus expressing Rybp (Ad-Rybp). Infection with Ad-Rybp inhibits the proliferation of a range of tumor cell lines, but has no effect on normal cell types. This inhibition of proliferation is the result of the induction of apoptosis, consistent with reports that Rybp regulates apoptosis. Combined Ad-Rybp infection and etoposide treatment resulted in an additive cytotoxic effect in the osteosarcoma cell line U20S. Furthermore, Ad-Rybp infection synergistically cooperates with the death receptor ligand, tumor necrosis factor-a, in the induction of apoptosis. These results suggest that Ad-Rybp may have clinical applicability, either alone or in combination with other agents for the treatment of cancer.
Introduction
A pre-requisite for successful cancer gene therapy is a mechanism to specifically target tumor cells for cell death or growth inhibition. Approaches to generate tumor specificity include the reintroduction of tumor suppressor genes that are deleted in cancer cells to reactivate impaired growth suppression pathways. 1 Conversely, inhibition of oncogenes that promote tumor survival and growth by introduction of antisense or short hairpin RNAs has been employed. 1 Additional approaches include the use of tumor-specific promoters driving the expression of suicide genes and the generation of oncolytic adenovirus that replicates only in tumor cells harboring tumor-specific mutations. 1 A less-utilized strategy to generate tumor specificity is the use of genes encoding proteins with tumor-specific killing activity. A limited number of proteins have been identified that are cytotoxic to transformed cells but not normal cells. 2 One example is the chicken cell anemia virus protein, apoptin. 2 When introduced into normal cells, apoptin is located in the cytoplasm, but in transformed cells it is located in the nucleus. 2 This nuclear location of apoptin is essential for its tumorpreferential killing properties, 2 although how nuclear apoptin promotes apoptosis is not well understood. Recent studies have identified two cellular proteins that contribute to apoptin-mediated tumor-specific killing, the orphan nuclear receptor, Nur77, and Rybp (Ring 1 YY1-binding protein or DEDAF). 3, 4 Rybp is a member of the Polycomb group family of proteins that function in multi-protein transcriptional repressive complexes to promote heritable gene silencing. [5] [6] [7] A role for Rybp as a transcriptional repressor in mammalian cells is supported by its ability to interact and repress the transcriptional activity of several sequencespecific transcription factors. 6, [8] [9] [10] Genetic evidence from mice and flies establishes that the transcriptional repressive properties of Rybp are important for normal development and suggests a physiological role in the induction of apoptosis. 5, 11, 12 A role as a promoter of cell death is supported by evidence that Rybp enhances Fas-induced apoptosis. 13 When the Fas receptor is bound by ligand, the adaptor molecule Fas associated protein with death domain (FADD) interacts with pro-caspase-8 and pro-caspase-10 to form the death-inducing signaling complex (DISC).
death-receptor signaling. 13, 14 In addition, Rybp can also interact with the DED-containing DNA-binding protein (DEDD) in the nucleus. 13 In response to apoptotic signals, DEDD is translocated from the cytoplasm to the nucleus where it promotes apoptosis. 15 Rybp expression promotes the relocalization of DEDD within the nucleus, suggesting that Rybp regulates DED-containing proteins in both the nucleus and the cytoplasm. 13 Like apoptin, Rybp also enhances apoptosis exclusively in tumor cells. 4 This tumor-specific killing property of Rybp makes it a potential candidate for use in a gene therapy approach. To assess the potential of Rybpexpressing viral vectors to treat cancer, we generated an adenoviral vector expressing Rybp (Ad-Rybp). Adenoviral vectors have been extensively utilized in gene therapy approaches and offer a number of advantages including the ability to infect a large array of human tissue (both dividing and non-dividing cells), the ease of production of high-titer replication-deficient virus and epichromosomal expression of transgenes. 16, 17 Our experiments demonstrate that infection with Ad-Rybp is cytotoxic to a variety of tumor cell types, while sparing normal cell types. Ad-Rybp infection inhibits cell growth by the induction of apoptosis and sensitizes tumor cells to the cytotoxic effect of tumor necrosis factor-a (TNF-a) and etoposide. Our data suggest that Rybp has potential for use as a cancer gene therapy agent, either as alone or in combination with current cancer treatments.
Materials and Methods
Cell culture U2OS, SAOS2, A549, H1299, HEK 293A, MRC5 and IMR90 cell lines were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (Hyclone, Logan, UT, USA), 2 mM L-glutamine (Cellgro, Manassas, VA, USA), 100 U ml À1 penicillin and streptomycin (Cellgro). TOV112 and TOV21 cell lines were maintained in 50:50 mixture of MCBD (Sigma, St Louis, MO, USA) and MI99 (Cellgro) media supplemented with 15% fetal bovine serum. RPE (retinal pigmented epithelial cells) and RPE-E1A (RPE cells expressing the oncogene E1a) cell lines were maintained in Dulbecco's modified F12 medium supplemented with 10% fetal bovine serum, 2 mM L-glutamine (Cellgro), 100 U ml À1 penicillin and streptomycin (Cellgro).
Construction, generation and purification of Ad-Rybp and Ad-GFP Adenoviral vectors were generated using the protocol described by He et al. 18 with minor modifications. Briefly, the human full-length coding sequence of Rybp gene containing an N-terminal Myc-tag was cut from the pcDNA3-Myc Rybp (a gift from Dr Joseph Nevins) with BamHI/EcoR1 and subcloned into the pAdTrack-CMV-GFP vector (a gift from Dr Bert Vogelstein) to generate pAdTrack-Rybp. pAdTrack-Rybp and pAdTrack-GFP clones were linearized with EcoRI and used to transform the BJ5183 electrocompetent bacteria containing the Ad-Easy Adenoviral vector (Stratgene, La Jolla, CA, USA). Colonies containing recombination products from AdEasy and AdTrack vectors were picked and analyzed by PacI digestion to identify correct recombination clones. Selected clones were linearized with PacI and transfected into the HEK 293A cell line (Clontech, Mountain View, CA, USA) to produce recombinant adenovirus containing either GFP (Ad-GFP) or Rybp (Ad-Rybp). Virus was amplified and purified using the Adeno-X Virus purification kit according to the manufacturer's protocol (Clontech).
Determination of viral titers
To calculate viral titers, 3 Â 10 4 U2OS cells were incubated with a series of dilutions of Ad-GFP or AdRybp for 24 h. Cells were trypsinized, fixed with 4% parafomaldehyde for 15 min at room temperature and permeabilized in methanol overnight at 4 1C. Cells were then blocked in a 3% bovine serum albumin/phosphatebuffered saline (BSA/PBS) solution for 30 min, incubated with anti-GFP antibody (Becton Dickinson Biosciences, San Diego, CA, USA) (1:200 in blocking solution) for 2 h on ice, followed by incubation with the anti-mouse fluorescein isothiocyanate-conjugated antibody (1:10 in PBS) (DAKO, Carpinteria, CA, USA) for 1 h on ice. Cells were then incubated in a PBS solution containing propidium iodide (50 mg ml À1 ) (Fisher Scientific, Pittsburgh, PA, USA) and RNAse A (50 mg ml À1 ) (Sigma) for 30 min and analyzed for DNA content and GFP fluorescence by flow cytometry. Viral titers were calculated by using dilutions of virus that gave approximately 10% GFPpositive cells. The calculation of infectious particles assumes that infection with a single virus is sufficient to express GFP to a level detectable by flow cytometry.
Immunoblotting
Cell lysates were collected in 2 Â sample buffer at 2 Â 10 3 cells per ml, and 30 ml of lysate was resolved on a 10% SDS-polyacrylamide gel electrophoresis. Proteins were transferred to a polyvinylidene difluoride membrane (Hybond-P) (Amersham, Piscataway, NJ, USA) and blocked in TBST containing 5% skimmed milk. Membranes were incubated for 1 h with primary antibody anti-GFP (Becton Dickinson Biosciences), anti-Myc (sc-40) (Santa Cruz) and anti-actin (Sigma). Membranes were then washed in TBST and incubated for 1 h with horseradish peroxidase-conjugated anti-mouse antibody (Amersham Biosciences) and washed in tris buffered saline tween-20 (TBST). Protein bands were visualized by chemiluminescence using ECL (Pierce, Rockford, IL, USA).
Immunofluorescence
Cells were grown on glass coverslips and fixed with 4% paraformaldehyde at room temperature for 10 min. Coverslips were washed three times with PBS, permeabilized with 0.2% Triton X-100/PBS for 5 min and then blocked for 30 min (2% goat serum in PBS) at room temperature. Cells were then incubated with anti-Myc antibody (1:200 in 2% goat serum/PBS) overnight at 4 1C followed by incubation with anti-mouse Alexa 594 (Molecular Probes) for 1 h at room temperature. Cells were then washed and stained with 30 mM 4 0 ,6-diamidino-2-phenylindole (Sigma) for 20 min at room temperature and mounted on glass slides using the anti-fade kit (Molecular Probes).
Proliferation assays and crystal violet staining Cells were plated at 3 Â 10 3 or 5 Â 10 3 in 96-well plates and infected with 2, 8 or 15 Infectious Particles per Cell (IP/C) of either Ad-GFP or Ad-Rybp as indicated in the figure legends. The cells were harvested at the time points indicated and stained with crystal violet. For crystal violet staining, cells were washed twice in PBS and fixed with methanol for 30 min at room temperature. Cells were stained with crystal violet (0.1% crystal violet (w/v) in PBS and 25% methanol) for 1 h at room temperature, washed twice with water and allowed to air dry for 1 h. Crystal violet was eluted from cells by adding 10% acetic acid for 2 min and elutants were read on a microplate reader at 595 nm. For each experiment and cell type, defined numbers of cells were plated 2 h prior to harvest and were used to generate a standard curve of optical density 595 nm against cell number. Optical density values at 595 nm of experimental samples were converted to cell number using the standard curve. The results are the average of three independent experiments. ) and RNase A (Sigma; 50 mg ml À1 ). DNA content was analyzed by flow cytometry as previously described, and cells with less than 2N DNA were scored as apoptotic. 19 Caspase-3/7 activity assay Cells were plated at 5 Â 10 3 in 96-well plates and infected with 15 IP/C of adenovirus for 48 h. Cell numbers were determined and cells were lyzed and analyzed for caspase-3/7 activity using the Caspase-Glo 3/7 assay kit according to the manufacturer's instructions (Promega, Madison, WI, USA). Caspase-3/7 activity was normalized for cell number and was plotted as the average fold increase over uninfected cells. The results presented are the average and standard deviation from three independent experiments.
Death receptor ligand and chemotherapeutic treatments U2OS and A549 cells were plated at 5 Â 10 3 in 96-well plates and infected with Ad-GFP or Ad-Rybp as indicated. Twenty-four hours postinfection, cells were treated with TNF-a (Endogen, Rockford, IL, USA), cisplatin (Bedford Laboratories, Bedford, OH, USA) or etoposide (MP Biomedicals, Solon, OH, USA) at the indicated concentrations for an additional 24 or 48 h. Cells numbers were calculated following crystal violet staining as described above. Results presented are the average and standard deviations from three independent experiments.
Statistical analysis P-values were determined by Student's t-tests using Prism 4 software. Statistical significance is represented in figures by *, where * equals a P-value between 0.01 and 0.05, ** indicates a P-value between 0.001 and 0.01 and *** indicates a P-valueo0.001.
Results

Generation of recombinant adenovirus expressing Rybp
To test if viral-mediated delivery of Rybp has tumorspecific killing activity, we generated replicative-deficient adenovirus expressing Rybp (Ad-Rybp). The human Rybp coding sequence containing an N-terminal Mycepitope tag was subcloned into the Ad-Track-CMV-GFP plasmid, and recombinant adenovirus expressing both Rybp and GFP (Ad-Rybp) was generated (see Materials and Methods). As a control, adenovirus expressing only GFP (Ad-GFP) was generated. To determine viral titers of Ad-GFP and Ad-Rybp, the osteosarcoma cell line, U2OS, was infected with dilutions of each virus. At 24 h postinfection, the number of GFP-positive cells was determined by flow cytometry (data not shown) and viral titers were calculated (see Materials and Methods).
To confirm that adenoviral infection resulted in expression of Rybp and/or GFP, U2OS cells were infected and analyzed by fluorescence microscopy 24 h postinfection ( Figure 1a ). As expected, over 80% of cells in cultures exposed to 2 IP/C of either Ad-GFP or Ad-Rybp were positive for GFP expression (Figure 1a ). Ad-GFPinfected cells were slightly more fluorescent than AdRybp-infected cells, although a similar percentage of cells expressed GFP (Figure 1a) . Only the Ad-Rybp-infected cells stained positive for Myc-Rybp (Figure 1a ). This staining is exclusively nuclear and has a punctate pattern (Figure 1a) , which has been reported by other investigators and presumably reflects the presence of Rybp in Polycomb bodies. 6 Western blot analysis of lysates from infected cultures was used to confirm the efficient expression of GFP and Myc-Rybp. Ad-GFP-infected cells have higher GFP levels than those infected with Ad-Rybp (Figure 1b ). This result is consistent with both the flow cytometry and immunofluoresence experiments indicating that Ad-Rybp expresses GFP at a lower level than the Ad-GFP (data not shown and Figure 1a) . The anti-Myc antibody recognized a band only in the Ad-Rybp-treated cells, demonstrating that the virus efficiently drives expression of Myc-Rybp (Figure 1b) . These blots were re-probed with the anti-actin antibody and similar levels of actin were observed in all lanes, confirming equal loading of the cell lysates (Figure 1b) . These results indicate that sensitivity to Ad-Rybpmediated inhibition of proliferation is not due to differences in the expression levels of Rybp.
Previous reports demonstrate that normal cells, including human foreskin fibroblasts and mesenchymal stem cells, are resistant to Rybp-mediated death. 4 To test if adenoviral delivery of Rybp similarly failed to inhibit the proliferation of non-transformed cells, we compared the cell number of non-transformed cells infected with 8 IP/C of Ad-GFP and Ad-Rybp at 48 h postinfection. Telomerase-immortalized RPE and normal diploid human fibroblast lines MRC5 and IMR90 were resistant to Ad-Rybp-mediated growth inhibition (Figure 3c ). These results demonstrate that Ad-Rybp retains the tumor-specific killing activity reported in the literature. 4 Transformation of normal diploid fibroblasts with SV40 was able to convert these cells to an Rybp-sensitive phenotype. 4 To investigate if introduction of an oncogene into non-transformed cells rendered them sensitive to Ad-Rybp, we compared the ability of Ad-Rybp to inhibit the growth of the isogenic lines RPE and RPE-E1A. Ad-Rybp-infected RPE cells display no reduction in cell number when compared to Ad-GFP-infected control cultures (Figure 3c ). In contrast, infection with Ad-Rybp results in a 70% reduction of RPE-E1A cells compared to Ad-GFP-infected control cells (Figure 3c ). These results suggest that the disruption of normal growth regulation pathways by oncogenes is sufficient to render cells sensitive to Rybp-induced apoptosis. 4 Analysis of MycRybp and GFP expression following infection demonstrated that the differences in sensitivity to Ad-Rybp were not a result of differences in expression (Figure 3d ).
Ad-Rybp induces apoptosis
Infection of either U2OS or A549 cells with Ad-Rybp resulted in almost the complete elimination of the cell cultures by 72 h at viral concentration of 15 IP/C (Figure 2 ). These results suggest that Rybp inhibits cell proliferation, at least in part, by promoting cell death. This is consistent with the work from other investigators indicating that Rybp promotes apoptosis. 4, 13 To determine if Ad-Rybp inhibits proliferation by inducing apoptosis or by a combination of apoptosis and cell cycle arrest, DNA content of Ad-Rybp-and Ad-GFP-infected cells was measured by propidium iodide staining and flow cytometry. This assay allows the determination of the proportion of cells in each phase of the cell cycle. In addition, as DNA fragmentation is a characteristic of cells undergoing apoptosis, we can also use this as an assay of apoptosis, with cells with less than a 2N DNA content scored as apoptotic. We detect no significant changes in cell cycle distribution of Ad-Rybp-infected cells compared to uninfected controls up to 48 h postinfection (Figure 4a ). However, apoptotic cells are detected 36 h post-Ad-Rybp infection, and the fraction of apoptotic cells increased to 30% by 48 h (Figure 4a ). The lack of any apoptosis at the 24-h time point is consistent with the results from the growth curves showing no difference in cell numbers between AdRybp-and Ad-GFP-infected cultures at 24 h (Figure 2a) . Ad-GFP-infected cultures displayed a similar level of apoptosis compared to the uninfected control up to 48 h postinfection, indicating that the apoptosis is dependent on expression of Rybp (Figure 4a) . Similar experiments were performed in A549 cells (Figure 4b) . At 48 h postinfection with Ad-Rybp, the number of A549 cells undergoing apoptosis increased to 24% (Figure 4b) .
Caspases are proteases that function as regulators and effectors of the apoptotic process, and elevated activity is a characteristic of a cell undergoing apoptosis. As an additional measure of apoptosis, Ad-GFP-and Ad-Rybpinfected cells were assayed for caspase-3/7 activity. Ad-Rybp-infected cultures had a 12.4-fold increase in caspase-3/7 activity compared to uninfected and Ad-GFP-infected cells at 48 h postinfection (Figure 4c ). This increase in caspase activity is consistent with an apoptotic mechanism of cell death.
To determine if caspase activity was necessary for AdRybp-mediated death, the ability of Ad-Rybp to induce apoptosis was compared with and without treatment with the broad-specificity caspase inhibitor Z-VAD (Figure 4d ). U20S cells were infected with Ad-Rybp (with and without Z-VAD) and analyzed for DNA content. At 48 h postinfection, Ad-Rybp cultures contained an average of 36% apoptotic cells (Figure 4d ). In the presence of Z-VAD, Ad-Rybp-induced apoptosis was reduced to almost background level (Figure 4d ). Taken together, these data demonstrate that Ad-Rybp infection inhibits proliferation of tumor cells by promoting apoptosis (Figures 4a-d) .
Ad-Rybp cooperates with chemotherapeutic agents to inhibit tumor cell proliferation As gene therapy is most likely to be successful when combined with other therapeutic approaches such as chemotherapy, 20 we sought to determine if Ad-Rybp infection sensitizes cells to the cytotoxic effects of the chemotherapeutic agents. For the treatment of osteosarcoma and NSCLC, platinum based-therapies, such as cisplatin, are often used as a first-line treatment. 21, 22 Platinum compounds are either used alone or in combination with other non-platinum agents, including etoposide. 21, 22 As such, we tested if Ad-Rybp would sensitize U20S or A549 cells to the cytotoxic effects of cisplatin or etoposide treatments.
Proliferation of U2OS cells was measured in cells infected with sublethal viral concentrations of Ad-Rybp (2 IP/C) followed by etoposide or cisplatin treatment for 24 h. Etoposide inhibited the growth of Ad-GFP-infected cells with an IC 50 value 45 mM (Figure 5a ). Ad-Rybp infection cooperated with etoposide treatment, reducing the IC 50 value to 1 mM (Figure 5a ). Both Ad-Rybp-and Ad-GFP-infected cultures showed a similar sensitivity to cisplatin treatment, with total elimination of cells at 25 mM, although Ad-Rybp-infected cells were slightly more sensitive (Figure 5b) .
The cooperation between Ad-Rybp infection and etoposide and cisplatin treatment was also assessed in A549 cells. As A549 cells are more resistant to Ad-Rybp infection (Figures 2a and b) , cells were infected with 4 IP/ C of either Ad-GFP or Ad-Rybp and treated with either cisplatin or etoposide for 24 h. In contrast to the results in U20S cells, Ad-Rybp increased the cytotoxicity of either etoposide or cisplatin only marginally (Figures 5c and d) .
Ad-Rybp cooperates with the death receptor ligand TNF-a to inhibit tumor cell proliferation As Rybp has been reported to enhance Fas-mediated death in tumor cell lines, 13 we tested if Ad-Rybp sensitizes cells to an additional death receptor ligand, TNF-a. U2OS cells were infected with Ad-GFP or Ad-Rybp (2 IP/C) for 24 h followed by treatment with TNF-a for 24 h. Ad-GFP-infected cultures were completely resistant to the cytotoxic effects of TNF-a (Figure 6a) . In contrast, AdRybp-infected cells were extremely sensitive to TNF-ainduced cytotoxicity (Figure 6a ). Treatment with 2 ng ml À1 TNF-a was sufficient to eliminate all of the cells in the culture (Figure 6a) .
As TNF-a induces death receptor-mediated apoptosis, 23 we would expect that the changes in cell number in Figure 6a are due to apoptosis. To confirm this, AdRybp-and Ad-GFP-infected cultures of U2OS cells were treated with TNF-a and apoptosis was measured by flow cytometry (Figures 6b and c) . TNF-a treatment of Ad-GFP cultures modestly increased the proportion of apoptotic cells from 6 to 13% (Figures 6b and c) . In contrast, TNF-a treatment dramatically cooperated with Ad-Rybp in the induction of apoptosis, increasing the proportion of apoptotic cells from 13 to 48% (Figures 6b and c) . Similar experiments were performed to determine if Ad-Rybp sensitizes A549 cells to TNF-a-induced apoptosis. A549 cells were infected with Ad-GFP or Ad-Rybp (4 IP/C) followed by incubation with TNF-a, and cell numbers were determined at 24 and 48 h post-TNF-a treatment. Ad-Rybp infection did not increase the sensitivity to TNF-a at 24 h (data not shown). However, at 48 h of TNF-a (10 ng ml À1 ) treatment, there was an 80% reduction in the cell number of Ad-Rybp-infected cultures (Figure 6d ). In contrast, Ad-GFP-infected cultures were resistant to TNF-a-induced cytotoxicity at both 24 and 48 h (data not shown and Figure 6d) .
To determine if the reduction in cell number of AdRybp-and TNF-a-treated cultures is a result of increased apoptosis, A549 cultures were infected with Ad-GFP or Ad-Rybp, treated with TNF-a and DNA content was measured by flow cytometry (Figures 6e and f) . Treatment of Ad-GFP-infected cultures with TNF-a did not alter the cell cycle distribution or rate of apoptosis (Figures 6e and f) . In contrast, TNF-a treatment of Ad-Rybp-infected cultures resulted in a significant increase in the percentage of apoptotic cells when compared to Ad-Rybp infection alone (Figures 6e and  f) , with the percentage increasing from 16 to 40%.
Discussion
To test the applicability of viral-mediated delivery of Rybp as a therapeutic approach to treat cancer, we generated and characterized an adenoviral vector driving expression of Rybp. In this study, the effect of Ad-Rybp infection on the osteosarcoma U20S and the NSCLC A549 cell lines was characterized in detail. Ad-Rybp, but not control Ad-GFP, inhibited proliferation with effects detected at 48 h postinfection and was capable of eliminating almost all of the cells in the culture by 72 h (Figures 2 and 3) . This Ad-Rybp-mediated inhibition of proliferation is the result of the promotion of apoptosis with minimal effects on the cell cycle distribution (Figures  4a-d) . The induction of apoptosis in tumor cells by Ad-Rybp (Figures 3a and c) is consistent with the results reported by other investigators when Rybp was introduced by transfection. 4, 13 Successful gene therapy requires not just efficient killing, but tumor-cell specificity. Our results confirm tumor-preferential killing, with Ad-Rybp inhibiting proliferation of five of the six tumor cell lines tested in this study (Figure 3a) . In addition, we demonstrate that normal diploid fibroblast cell lines (IMR90 and MRC5) and telomerase-immortalized RPE are unaffected by Ad-Rybp infection (Figure 3c ). However, introduction of an oncogene into the RPE cells was sufficient to render these cells sensitive to Ad-Rybp-mediated growth inhibition (Figure 3c ). These results are consistent with other studies showing that Rybp induces apoptosis of tumor cell lines including Jurkat, H9, SW480 and SAOS2 and even in SV40-transformed human fibroblasts, but not a range of normal cells including chemosensitive mesenchymal stem cells. 4, 13 Our results demonstrate that Rybp retains its tumor-specific killing activity when introduced to cells by adenoviral transduction, suggesting that adenoviral vectors expressing Rybp may have clinical applicability.
Ad-Rybp infection inhibited the proliferation of all transformed cell lines tested with the exception of the NSCLC line H1299 (Figure 3a) . The mechanism of H1299 cell resistance to Rybp expression remains unclear. A trivial explanation of differential infectivity or expression levels was excluded as an additional NSCLC, A549, was sensitive despite showing lower levels of expression of Myc-Rybp (Figures 3a and b) . A critical mediator of apoptosis is p53. 24 This gene is retained in A549 but is lost in H1299, as such could underlie the differential sensitivity of these lines to Ad-Rybp infection. However, Ad-Rybp infection did not result in elevated levels of p53 or induce p53 target genes (data not shown). This result suggests that Rybp promotes apoptosis independently of p53, consistent with previous reports in the literature. 4 Gene therapy approaches in the clinic are most likely to be undertaken in combination with chemotherapy. 20 Both cisplatin and etoposide are used to treat a large variety of tumor types, including osteosarcoma and NSCLC, 21, 22 and for this reason we determined if Ad-Rybp would enhance the cytotoxic effects of these chemotherapeutic drugs. Ad-Rybp infection of U2OS cells increased the cytotoxicity of etoposide (Figure 5a ), with marginal, if any, enhancement of cisplatin cytotoxicity (Figure 5b ). In contrast, Ad-Rybp dramatically increased TNF-a cytotoxicity (Figures 6a-f) . The reason why Ad-Rybp enhances TNF-a-induced cytotoxicity so efficiently, but not etopside or cisplatin is unclear, but may reflect a difference in the apoptotic signals generated by each reagent.
The two major apoptotic pathways are the death receptor (or extrinsic) and the mitochondrial (or intrinsic) pathways. In both pathways, activation of the apical initiator caspase in turn activates other caspases. 25 This can lead to a hierarchy of caspase activation, resulting in the orderly dismantling of the cell. Activation of the mitochondrial pathway results in the release of mitochondrial-sequestered pro-apoptotic molecules including cytochrome c. 25 The release of cytochrome c promotes the formation of apoptosome, a complex between Apaf1 and pro-caspase-9, activating the apical caspase-9. 25 This pathway can be activated by a variety of stresses including cisplatin and etoposide. 26, 27 In contrast, TNF-a activates the death receptor resulting in the formation of a signaling complex activating the apical caspase-8. 23 A role for Rybp in the regulation of death receptor-induced apoptosis is supported by evidence that Rybp interacts with the death effector domain proteins FADD, caspase-8 and -10. 13 This interaction promotes DISC formation and enhances Fas-induced apoptosis. 13 This mechanism of promoting apoptosis would predict that Rybp would enhance apoptosis induced by other death receptor ligands, including TNF-a, by the promotion of caspase-8 and -10 activation. This hypothesis is supported by our results indicating dramatic cooperation between TNF-a and AdRybp in the induction of apoptosis (Figure 6 ).
An alternative (or complementary) mechanism of Rybp-induced cell death may be the transcriptional repression of a subset of antiapoptotic target genes. Although we have no direct evidence that Ad-Rybp induces apoptosis by the inhibition of transcription, the significant delay prior to the induction of apoptosis suggests an indirect mechanism, perhaps dependent on the modulation of transcription. Both biochemical and genetic approaches have provided persuasive evidence that Rybp is a part of a multiprotein transcriptional repressive complex. 5, 6, [8] [9] [10] [11] Inhibition of the transcription of proteins involved in the suppression of apoptosis is an attractive hypothesis to account for the potent apoptotic activity of Rybp. Our adenovirus expressing Rybp will be an excellent tool to identify Rybp-regulated genes and to nvestigate the mechanism of tumor-specific killing.
The work here indicates that adenoviral-mediated expression of Rybp can selectively induce apoptosis in human tumor cells. As such, it may have clinical applicability, either alone or in combination with other agents that activate apoptosis. The dramatic cooperation between TNF-a and Ad-Rybp suggests that activation of death receptor signaling may be the most effective combination. Due to toxicity, TNF-a is not used as an anticancer therapeutic. 28 However, future experiments to determine if Ad-Rybp enhances apoptosis of other clinically relevant activators of the extrinsic pathway, such as the deathreceptor ligand TNF-related apoptosis inducing ligand (TRAIL) or TRAIL-R-agonistic antibodies, are merited. 29 
